Documents
Médias
Medivir Announces Plans for a Phase II All-oral Study of Simeprevir (TMC435) and VX-135 for the Treatment of Hepatitis C to be Conducted by Janssen and Vertex
Editeur
Medivir-AB
Publications
(
1
)